IDENTIFYSENSORS INITIATES FDA SUBMISSION PROCESS FOR DIGITAL DIAGNOSTICS PLATFORM

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Regulatory authorization will signal the first electronic technology to detect a disease

CLEVELAND, May 20, 2025 /PRNewswire/ — IdentifySensors Biologics, a leading developer of digital diagnostic technologies, has initiated the FDA review process by submitting a pre-EUA for emergency use authorization of a rapid Ebola test on the company’s new Check4 platform.

When authorized, the diagnostic advancement will be the first platform that detects Ebola virus using nanomaterials on an electronic semiconductor. The company is developing similar biosensors for a wide range of infectious diseases that can be identified through the electrical reactions of DNA and RNA – down to the molecular level for high levels of accuracy.

Digitizing diagnostics on a small Bluetooth device offers a wide range of health-care advantages, including rapid results, database connectivity, location mapping, data collection, greater accessibility and facilitating faster treatment times. The platform is intended to be more user friendly and less expensive than similar tests.  

Unlike current molecular tests, which largely require laboratory work with skilled technicians, the Check4 platform is intended to be used virtually anywhere, any time. The company plans an ongoing pipeline of FDA submissions for infectious diseases, bacterial infections and other diseases that can be detected through genetic biomarkers.    

To date, the company has been issued 26 patents and raised $20 million to commercialize the technology. It is seeking additional funding and strategic partners to expand research and development.

“This is the new internet of things for diagnostics,” said IdentifySensors CEO Greg Hummer. “Current molecular tests are old, slow, expensive and require skilled labor. Our rapid detection platform solves that through electronic circuits that connect instantly to cloud-based algorithms and healthcare software systems.”

About IdentifySensors Biologics
IdentifySensors Biologics is a nano-biotech company driving a shift in molecular diagnostics from a hardware-heavy, laboratory-based delivery model to a low-cost, portable software-based delivery platform. The advancements leverage new nanomaterials in semiconductors and bioinformatics. For more information visit www.identifysensors.com

News Media Contact
Joe Mosbrook
mosbrook@acclaimllc.com
216-375-2141

View original content:https://www.prnewswire.com/news-releases/identifysensors-initiates-fda-submission-process-for-digital-diagnostics-platform-302460914.html

SOURCE IdentifySensors Biologics

Staff

Recent Posts

WellPact Achieves HITRUST i1 Certification to Manage Data Protection and Mitigate Cybersecurity Threats

HITRUST certification validates WellPact is operating leading security practices to protect sensitive information. ROARING SPRING,…

2 hours ago

Advanced Biological Research Group to Study Effects of mRNA on Women’s Reproduction

JACKSONVILLE, Fla., June 5, 2025 /PRNewswire/ -- Advanced Biological Research Group (ABRG), a 501c3, has…

2 hours ago

ImageTrend Ensures Continuity of EMS Data Reporting for Michigan Agencies

EAGAN, Minn., June 5, 2025 /PRNewswire/ -- The Michigan Department of Health and Human Services (MDHHS)…

2 hours ago

Archetype Announces Investment with Enrollment Management Services

PHILADELPHIA, June 5, 2025 /PRNewswire/ -- Archetype, a growth equity investment firm, has announced an…

2 hours ago

TALON and HealthAxis Announce Strategic Partnership to Exceed Member Expectations

PORTSMOUTH, N.H. and TAMPA, Fla., June 5, 2025 /PRNewswire/ -- TALON, the nation's leader in…

2 hours ago

Private Astronaut Mission Includes Research to Open Space to Astronauts With Diabetes and Enable Early Cancer Detection

Axiom Mission 4 partners with ISS National Lab to conduct the most research to date…

2 hours ago